Skip to main content

neoralabDiscovering molecules against antimicrobial resistance.

Bacteria evolve. Discovery must evolve faster.

Antimicrobial resistance was directly attributable to 1.27M deaths in 2019, and associated with 4.95M deaths overall — driven by pathogens that keep defeating conventional treatment paths.

Dotted-globe visualization of bacteria driving antimicrobial resistance worldwide
Scanning electron micrograph of a bacterial colony with a single resistant cell highlighted in green
  • MRSA (S. aureus)

    A persistent hospital-acquired threat, especially when severe infections turn systemic.

  • Pseudomonas aeruginosa

    A difficult ICU pathogen with resistance patterns that constrain standard treatment options.

  • Acinetobacter baumannii

    A recurrent source of bloodstream and respiratory infections in vulnerable patients.

We start where resistance hurts most — MRSA first.

Structure-based small-molecule optimization against priority pathogens, with several more on the list. We lead with MRSA because it combines:

  • Urgent, unmet clinical need
  • Rich structural data our workflow can exploit
  • A straightforward path to experimental validation
Coloured scanning electron micrograph of Staphylococcus aureus (MRSA) cell clusters

Three forces make structure-based AI discovery viable now.

Billions spent, decades lost.

Traditional discovery is slow, costly and fragmented — molecular discovery still runs on trial and error.

The AI stack is production-ready.

Agentic AI, docking and molecular dynamics now run as reproducible, chained workflows.

Pharma needs cost & time out.

R&D teams are under pressure to design candidates against high, unmet medical need.

Drug discovery is slow, costly, and fragmented.

neoralab is not another molecule generator. It is an AI-native discovery operating system.

It connects models, tools and data into one workflow, explains and stores every scientific decision, and delivers traceable, validation-ready candidates. With each completed project it builds knowledge — compounding its value over time.

Small-molecule drug candidate bound inside a protein binding pocket during structure-based docking

Four layers of compounding advantage

  1. Scientific memory layer

    A second brain — every project builds reusable, searchable knowledge.

  2. Agentic workflow engine

    Multi-agent systems coordinate literature, structures, tools and reporting.

  3. Explainable discovery

    Rationale, risks, analogs, sources and next experiments — every scientific decision stored.

  4. Closed-loop learning

    Experimental feedback refines ranking and decisions with each completed project.

Small Molecule Design

Generative design of novel small molecules optimized for a chosen biological target.

AMR Discovery

Antibiotic candidate discovery against resistant pathogens, from target to lead.

Custom AI Workflows

Bespoke agentic pipelines for molecular dynamics, docking, and candidate optimization.

Tell Us Your Idea

Bring your target or dataset and we build the discovery workflow around it.

Request access

Projects Portfolio

Selected research programs and collaborations in antimicrobial resistance and small molecule drug discovery, where our platform supports the full path from target to candidate.

Antibiotics discovery mood image

Antibiotics Discovery

In collaboration with academic researchers, we design AI-generated small molecules to tackle antibiotic resistance. Our platform integrates generative models, structure-based docking, and in-silico validation to accelerate early discovery and prioritize compounds with real translational potential.

Docking simulation mood image

Target-Oriented Small Molecule Design

We design small molecules starting from biological targets, combining generative AI with structure-aware evaluation to rapidly explore and refine candidate chemical space.

Research & News

Peer-reviewed publications and preprints from our researchers, advancing AI for drug discovery and biomedical data analysis.

  • LLMsFold: Integrating Large Language Models and Biophysical Simulations for De Novo Drug Design

  • Visual Exploratory Data Analysis for Copy Number Variation Studies in Biomedical Research

  • miRNAs Copy Number Variations Repertoire as Hallmark Indicator of Cancer Species Predisposition

  • VarCopy: a Visual Exploratory Data Analysis Platform for Copy Number Variation Studies

Beyond papers, we release the data, benchmarks, and validations behind our discoveries as open-source discovery — explore what we make public.

Explore open research
neoralab logo

Why neoralab

More than an AI platform, NeoraLab is a “Smart-Pharma” powerhouse. By integrating a dedicated discovery ecosystem with custom-built AI, we deliver advanced, data-driven solutions that redefine the frontier of life sciences.

Who We Are

We are a team of scientists, engineers, and builders focused on applied AI for life science research.

Fabio Bove

Fabio Bove

CEOCo-Founder

AI & Software Engineer

Marco Ferrarini

Marco Ferrarini

CSO

Master Degree in Medical Biotecnology

Federico Pratissoli

Federico Pratissoli

Co-Founder

PhD in Robotics and AI / Software Engineer

Alfredo Boracchini

Alfredo Boracchini

CFOCo-Founder

Engineer and Entrepreneur

Giovanni Caccialupi

Giovanni Caccialupi

PhD in Plant Genomics / Bioinformatics Scientist

Valentino Pisi

Valentino Pisi

Co-Founder

Data Analyst and Entrepreneur

Plantfoodomics Lab

University Cattolica

Research Group, Distas Department

Contact us

Tell us about your target, dataset, or workflow and we'll get back to you within 2 business days.

[email protected]

By submitting, you agree that we may contact you about this request.